• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C.

作者信息

Poynard T

出版信息

Gut. 2003 Oct;52(10):1532. doi: 10.1136/gut.52.10.1532.

DOI:10.1136/gut.52.10.1532
PMID:12970155
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1773838/
Abstract
摘要

相似文献

1
Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C.聚乙二醇化干扰素α-2b与利巴韦林联合治疗慢性丙型肝炎的成本效益
Gut. 2003 Oct;52(10):1532. doi: 10.1136/gut.52.10.1532.
2
Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.聚乙二醇化干扰素α-2a和α-2b联合利巴韦林治疗慢性丙型肝炎：系统评价与经济学评估
Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. doi: 10.3310/hta8390.
3
Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.聚乙二醇干扰素α-2b联合利巴韦林与干扰素α-2b联合利巴韦林用于初治慢性丙型肝炎的成本效益分析
Gut. 2003 Mar;52(3):425-32. doi: 10.1136/gut.52.3.425.
4
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.聚乙二醇干扰素联合利巴韦林治疗泰国慢性丙型肝炎1型和6型的经济学评价
BMC Gastroenterol. 2016 Aug 5;16(1):91. doi: 10.1186/s12876-016-0506-4.
5
Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.轻度慢性丙型肝炎抗病毒治疗的健康益处：随机对照试验与经济评估。
Health Technol Assess. 2006 Jul;10(21):1-113, iii. doi: 10.3310/hta10210.
6
Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C.
Hepatology. 2000 Mar;31(3):807-8. doi: 10.1002/hep.510310339.
7
Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.聚乙二醇干扰素α-2a或聚乙二醇干扰素α-2b联合利巴韦林治疗西班牙慢性丙型肝炎的药物经济学分析
Gastroenterol Hepatol. 2013 Nov;36(9):555-64. doi: 10.1016/j.gastrohep.2013.08.003. Epub 2013 Oct 9.
8
Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C.不同聚乙二醇干扰素α-2b联合利巴韦林治疗策略作为初治中国慢性丙型肝炎患者初始治疗的成本效用分析
Aliment Pharmacol Ther. 2006 Nov 15;24(10):1483-93. doi: 10.1111/j.1365-2036.2006.03105.x.
9
Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.干扰素α或聚乙二醇干扰素α联合利巴韦林治疗组织学轻度慢性丙型肝炎的成本效益
Gut. 2006 Sep;55(9):1332-8. doi: 10.1136/gut.2005.064774. Epub 2005 Jun 30.
10
Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.聚乙二醇干扰素α-2b联合利巴韦林与聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎的成本效益分析
J Manag Care Pharm. 2005 Oct;11(8):687-94. doi: 10.18553/jmcp.2005.11.8.687.

引用本文的文献

1
Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.聚乙二醇干扰素α-2b与利巴韦林联合治疗基因4型慢性丙型肝炎：治疗疗程和病毒动力学对持续病毒学应答的影响
Gut. 2005 Jun;54(6):858-66. doi: 10.1136/gut.2004.057182.
2
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.慢性丙型肝炎患者中肝纤维化（FibroTest、HCV FibroSure）和坏死（ActiTest）生化标志物的诊断价值概述
Comp Hepatol. 2004 Sep 23;3(1):8. doi: 10.1186/1476-5926-3-8.

本文引用的文献

1
Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.聚乙二醇干扰素α-2b联合利巴韦林与干扰素α-2b联合利巴韦林用于初治慢性丙型肝炎的成本效益分析
Gut. 2003 Mar;52(3):425-32. doi: 10.1136/gut.52.3.425.
2
A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.对慢性肝病患者纤维化生化标志物（FibroTest）和活性生化标志物（ActiTest）实验室间变异性的前瞻性评估。
Comp Hepatol. 2002 Dec 30;1(1):3. doi: 10.1186/1476-5926-1-3.
3
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.丙型肝炎病毒感染患者肝纤维化的生化标志物：一项前瞻性研究。
Lancet. 2001 Apr 7;357(9262):1069-75. doi: 10.1016/S0140-6736(00)04258-6.
4
Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.慢性丙型肝炎的预处理评估：风险、益处及成本
JAMA. 1998;280(24):2088-93. doi: 10.1001/jama.280.24.2088.